Indeed, we obtained comparable results in oxaliplatin-treated AGS (wild-type p53) and TMK-1 (mutant p53) gastric cancer cells (Fig. 4c), and noted that these findings were consistent with the profound apoptotic activity of oxaliplatin in AGS but not TMK-1 cells [9]. This evidence concerns the gene TP53 and gastric cancer.